Expression and function of ATP6V1C1 in hepatocellular carcinoma

doi:10.3760/cma.j.issn.1007-1245.2022.09.021

Abstract

Abstract: Objective　To investigate the expression and function of ATP6V1C1 in hepatocellular carcinoma (HCC). Methods　This was a basic study. The sequencing data from the Cancer Genome Atlas database GEO (Gene Expression Omnibus) were used to identify the differentially expressed genes in HCC (P<0.01, |logFc|≥1), and the data from the TCGA (The Cancer Genome Atlas) online data UALCAN and Timer were used to analyze the expressions and function of ATP6V1C1 in different stages of HCC. The TCGA database contained 121 female patients and 281 male patients, and they were 16-81 years old. KEGG signaling was used to understand the effect of ATP6V1C1 on the relevant pathways. The pcDNA3.1(+)-ATP6V1C1 vector was constructed, and the siRNA interference fragments were purchased to study the effect of ATP6V1C1 on hepatocellular carcinoma in vitro. The independent-sample t test was used. Results　Bioinformatics analysis suggested that ATP6V1C1 was upregulated in a variety of cancers (P<0.05); ATP6V1C1 expression correlated with HCC stage; and in patients with HCC, the patients with upregulated ATP6V1C1 expression had a worse prognosis than those with downregulation (P<0.05). The overexpression of ATP6V1C1 significantly promoted the invasion, migration, proliferation, and clone-forming ability of HCC cells, while interference with ATP6V1C1 inhibited the invasion, migration, proliferation, and clone-forming ability of HCC cells. Conclusions　ATP6V1C1 expression in HCC correlates with prognosis. This study provides a new possible diagnostic and therapeutic target for HCC.

Key words: ATP6V1C1, HCC, Bioinformatics analysis, Biological function, Prognosis

摘要： 目的　探究ATP6V1C1在肝细胞癌（HCC）表达情况及功能。方法　本研究为基础研究，利用来自癌症基因组图谱数据库基因表达总库（GEO）测序数据，找出HCC差异表达基因（P<0.01，|logFc|≥1），进一步利用来自于癌症基因组图谱（TCGA）在线数据UALCAN、Timer分析ATP6V1C1在HCC不同分期的表达情况及不同表达水平的预后情况，The Human Protein Atlas分析正常肝组织与肿瘤组织免疫组化。TCGA数据库包含女性患者121例，男性患者281例，年龄16～81岁，数据分析后台自行完成。KEGG信号了解ATP6V1C1对相关通路的影响。构建pcDNA3.1（+）-ATP6V1C1载体，购买siRNA干扰片段体外研究ATP6V1C1对肝细胞癌的影响。统计学方法采用独立样本t检验。结果　生物信息学分析提示ATP6V1C1在多种癌症中上调（P<0.05），ATP6V1C1的表达水平与HCC的肿瘤分级有关，在肝癌患者中，ATP6V1C1表达上调患者相对下调患者预后更差（P<0.05）。过表达ATP6V1C1后明显促进HCC细胞的侵袭、迁移、增殖及克隆形成能力，同时，干扰ATP6V1C1抑制HCC细胞的侵袭、迁移、增殖及克隆形成能力。结论　ATP6V1C1在HCC中表达与预后相关，这个研究为HCC提供了新的可能诊断及治疗靶标。

关键词: ATP6V1C1, 肝癌, 生物信息学分析, 生物学功能, 预后

Jiang Min, Zhao Yujun. Expression and function of ATP6V1C1 in hepatocellular carcinoma[J]. International Medicine and Health Guidance News, 2022, 28(9): 1270-1276.

姜敏, 赵玉军. ATP6V1C1在肝细胞癌中的表达及功能研究[J]. 国际医药卫生导报, 2022, 28(9): 1270-1276.

References

[1] Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 686: 394-424. DOI:10.3322/caac.21492.

[2] Orcutt ST, Anaya DA. Liver resection and surgical strategies for management of primary liver cancer[J]. Cancer Control, 2018, 25(1): 1073274817744621. DOI:10.1177/1073274817744621.

[3] Llovet J M, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma[J]. N Engl J Med, 2008, 359(4): 378-390. DOI:10.1056/NEJMoa0708857.

[4] Llovet JM, Montal R, Sia D, et al. Molecular therapies and precision medicine for hepatocellular carcinoma[J]. Nat Rev Clin Oncol, 2018, 15(10): 599-616. DOI:10.1038/s41571-018-0073-4.

[5] Oliveira Alves MG, Carta CF, Padín-Iruegas ME, et al. Expression of ATP6V1C1 during oral carcinogenesis[J]. Biotech Histochem, 2016, 91(4): 263-268. DOI:10.3109/10520295.2016.1144078.

[6] Pérez-Sayáns M, Reboiras-López MD, Somoza-Martín JM, et al. Measurement of ATP6V1C1 expression in brush cytology samples as a diagnostic and prognostic marker in oral squamous cell carcinoma[J]. Cancer Biol Ther, 2010, 9(12): 1057-1064. DOI:10.4161/cbt.9.12.11880.

[7] Otero-Rey EM, Somoza-Martín M, Barros-Angueira F, et al. Intracellular pH regulation in oral squamous cell carcinoma is mediated by increased V-ATPase activity via over-expression of the ATP6V1C1 gene[J]. Oral Oncol, 2008, 44(2): 193-199. DOI:10.1016/j.oraloncology. 2007.02.011.

[8] García-García A, Pérez-Sayáns M, Rodríguez MJ, et al. Immunohistochemical localization of C1 subunit of V-ATPase (ATPase C1) in oral squamous cell cancer and normal oral mucosa[J]. Biotech Histochem, 2012, 87(2): 133-139. DOI:10.3109/10520295.2011.574647.

[9] Yao X, Chen H, Xu B, et al. The ATPase subunit of ATP6V1C1 inhibits autophagy and enhances radiotherapy resistance in esophageal squamous cell carcinoma[J]. Gene, 2021, 768: 145261. DOI:10.1016/j.gene.2020. 145261.

[10] Chandrashekar DS, Bashel B, Balasubramanya SAH, et al. UALCAN: a portal for facilitating tumor subgroup gene expression and survival analyses[J]. Neoplasia, 2017, 19(8): 649-658. DOI:10.1016/j.neo.2017.05.002.

[11] LI T, Fan J, Wang B, et al. TIMER: a web server for comprehensive analysis of tumor-infiltrating immune cells[J]. Cancer Res, 2017, 77(21): e108-e110. DOI:10.1158/0008-5472.CAN-17-0307.

[12] Kanehisa M, Furumichi M, Tanabe M, et al. KEGG: new perspectives on genomes, pathways, diseases and drugs[J]. Nucleic Acids Res, 2017, 45(D1): D353-D361. DOI:10.1093/nar/gkw1092.

[13] Kim J, Kundu M, Viollet B, et al. AMPK and mTOR regulate autophagy through direct phosphorylation of Ulk1[J]. Nat Cell Biol, 2011, 13(2): 132-141. DOI:10.1038/ncb2152.

[14] Li X, He S, Ma B. Autophagy and autophagy-related proteins in cancer[J]. Mol Cancer, 2020, 19(1): 12. DOI:10.1186/s12943-020-1138-4.

[15] Wang X, Lan Z, He J, et al. LncRNA SNHG6 promotes chemoresistance through ULK1-induced autophagy by sponging miR-26a-5p in colorectal cancer cells[J]. Cancer Cell Int, 2019, 19: 234. DOI:10.1186/s12935-019-0951-6.

[16] Feng S, Deng L, Chen W, et al. Atp6v1c1 is an essential component of the osteoclast proton pump and in F-actin ring formation in osteoclasts[J]. Biochem J, 2009, 417(1): 195-203. DOI:10.1042/BJ20081073.

[17] 中华预防医学会肝胆胰疾病预防与控制专业委员会,中国研究型医院学会肝病专业委员会,中华医学会肝病学分会,等. 原发性肝癌的分层筛查与监测指南(2020版)[J]. 临床肝胆病杂志,2021,37(2):286-295. DOI:10.3969/j.issn.1001-5256.2021.02.009.

[18] Jing F, Geng Y, Xu XY, et al. MicroRNA29a reverts the activated hepatic stellate cells in the regression of hepatic fibrosis through regulation of atpase H+ transporting V1 subunit C1[J]. Int J Mol Sci, 2019, 20(4): 796. DOI:10.3390/ijms20040796.

[19] Wang Y, Chen W, Hao L, et al. C1 silencing attenuates inflammation and alveolar bone resorption in endodontic disease[J]. J Endod, 2019, 45(7): 898-906. DOI:10.1016/j.joen.2019.02.024.

[20] Li S, Hao L, Wang L, et al. Targeting Atp6v1c1 prevents inflammation and bone erosion caused by periodontitis and reveals its critical function in osteoimmunology[J]. PLoS One, 2015, 10(8): e0134903. DOI:10.1371/journal.pone.0134903.

[21] 于慧敏,李雪华. PI3K-AKT-mTOR信号通路在肝癌组织中的表达及意义[J]. 国际医药卫生导报,2019,25(8):1248-1251. DOI:10.3760/cma.j.issn.1007-1245. 2019. 08.020.

[22] Cai M, Liu P, Wei L, et al. Atp6v1c1 may regulate filament actin arrangement in breast cancer cells[J]. PLoS ONE, 2014, 9(1): e84833. DOI:10.1371/journal.pone.0084833.